Federal judge considers Bureau of Prisons policy on hormone treatments for inmates
A federal judge heard arguments Wednesday over whether the Bureau of Prisons can phase out taxpayer-funded hormone drugs for inmates diagnosed with gender dysphoria. The hearing addressed a class-action lawsuit challenging an executive order directing agencies to stop funding such treatments.
washingtonpost.comA federal judge on Wednesday considered whether the Bureau of Prisons can implement a policy that phases out taxpayer-funded hormone drugs for federal inmates diagnosed with gender dysphoria. The hearing addressed a class-action lawsuit challenging an executive order directing federal agencies to stop spending taxpayer funds on surgeries and drugs intended to help prisoners conform to the opposite sex.
The judge temporarily renewed an existing injunction blocking portions of the order while considering an updated preliminary injunction.
Background of the policy The Bureau of Prisons policy bars sex reassignment surgeries and social accommodations. It generally requires inmates currently receiving cross-sex hormones to taper off treatment over time. Officials stated the policy followed a review of medical studies, prison-security concerns, and debates surrounding gender dysphoria treatment.
The filing said prison officials concluded that psychotherapy, trauma treatment, and psychotropic medications were safer and more appropriate approaches in the prison setting.
Arguments presented A Justice Department attorney argued the policy is not a categorical ban because inmates receive individualized tapering plans and case-by-case review. The attorney said inmates must bring individualized claims rather than attempt to block the policy through a class-action suit.
An attorney representing the class of transgender inmates argued the policy is effectively a blanket ban because every inmate receiving hormone therapy is still expected to stop treatment eventually. The attorney said the individualized tapering plans merely manage withdrawal symptoms rather than allow doctors to determine whether hormone therapy remains medically necessary.
Scope of the litigation There are around 600 inmates across federal prisons who have been diagnosed with gender dysphoria, according to federal prison data. The class includes violent offenders and gang members seeking continued access to taxpayer-funded hormone drugs and transgender accommodations.
The hearing arrives days after the judge renewed an injunction blocking the administration from transferring biological men who identify as women into men's prisons. At the close of Wednesday's hearing, the judge said a decision would be issued promptly.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
Fox NewsJustice Department Abandons $1.8 Billion Anti-Weaponization Fund
Acting Attorney General Todd Blanche told Congress the department will not proceed with the fund. A separate agreement shielding President Donald Trump and his businesses from past IRS claims remains in place.
**Trump Administration Scraps $1.8 Billion Compensation Fund**
The Justice Department will not create a planned $1.8 billion fund intended to compensate people who say they were improperly targeted by federal law enforcement. Acting Attorney General Todd Blanche told lawmakers the department is abandoning the program entirely.
The HillPentagon Appoints Elias Irizarry, Who Participated in January 6 Capitol Riot at Age 19, to Special Operations Office
Elias Irizarry, who pleaded guilty to entering a restricted building during the January 6, 2021, Capitol events, has been named to a position in the Office of Special Operations and Low Intensity Conflict.